Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients (Q34485539)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

title

Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

triple-negative breast cancer

21 March 2020

main subject

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Ryuji Takahashi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Nobutaka Iwakuma

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Miki Takenaka

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Hiroko Otsuka

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Mina Furukawa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Teruhiko Fujii

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Naoko Seki

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Akihiko Kawahara

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Masayoshi Kage

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Satoko Matsueda

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Yoshito Akagi

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Akira Yamada

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Kyogo Itoh

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

Tetsuro Sasada

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

publication date

3 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

published in

Breast Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

R70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Combination anastrozole and fulvestrant in metastatic breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Targeting EGFR in Triple Negative Breast Cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Triple-Negative Breast Cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Triple-negative breast cancer: clinical features and patterns of recurrence

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Immunohistochemical expression of androgen receptor and prostate-specific antigen in breast cancer.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

6 July 2018

1 reference

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.

21 January 2018

1 reference

Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients.

21 January 2018

1 reference

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial

21 January 2018

1 reference

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

21 January 2018

1 reference

Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer

21 January 2018

1 reference

A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4227005

New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization

27 October 2018

1 reference

12 December 2020

Cancer-testis antigen expression in triple-negative breast cancer

1 reference

12 December 2020

Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination

1 reference

12 December 2020

Albumin-bound Paclitaxel: in metastatic breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/BCR3685

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

21 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json

21 March 2020

PubMed publication ID

24992895

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24992895%20AND%20SRC:MED&resulttype=core&format=json